Depression drug trial halted early – what happened?

NCT ID NCT06618118

Terminated Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new medicine called fosigotifator for adults with major depressive disorder. The goal was to see if it is safe and helps with depression symptoms. About 20 people were enrolled before the study was stopped early. Participants took either the drug or a placebo, and researchers checked for side effects and mood changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER (MDD)

Contacts and locations

Locations

CenExel CNR /ID# 265866

Sherman Oaks, California, 91403, United States
CenExel iResearch, LLC /ID# 265886

Decatur, Georgia, 30030-3440, United States
Clinical Neuroscience Solutions - Orlando - East South Street /ID# 265060

Orlando, Florida, 32801, United States
Northwest Clinical Research Center /ID# 265057

Bellevue, Washington, 98007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.